1.Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis.
Arthur Yin FAN ; Sherman GU ; Sarah Faggert ALEMI
Journal of Integrative Medicine 2020;18(5):385-394
BACKGROUND:
There is currently no drug or therapy that cures COVID-19, a highly contagious and life-threatening disease.
OBJECTIVE:
This systematic review and meta-analysis summarized contemporary studies that report the use of Chinese herbal medicine (CHM) to treat COVID-19.
SEARCH STRATEGY:
Six electronic databases (PubMed/MEDLINE, Cochrane Library, ScienceDirect, Google Scholar, Wanfang Data and China National Knowledge Infrastructure) were searched from their beginning to May 15, 2020 with the following search terms: traditional Chinese medicine, Chinese medicine, Chinese herbal medicine, COVID-19, new coronavirus pneumonia, SARS-CoV-2, and randomized controlled trial.
INCLUSION CRITERIA:
Randomized controlled trials (RCTs) from peer-reviewed journals and non-reviewed publications were included. Further, included RCTs had a control group that was given standard care (SC; such as conventional Western medicine treatments or routine medical care), and a treatment group that was given SC plus CHM.
DATA EXTRACTION AND ANALYSIS:
Two evaluators screened and collected literature independently; information on participants, study design, interventions, follow-up and adverse events were extracted, and risk of bias was assessed. The primary outcomes included scores that represented changes in symptoms and signs over the course of treatment. Secondary outcomes included the level of inflammatory markers, improvement of pneumonia confirmed by computed tomography (CT), and adverse events. Dichotomous data were expressed as risk ratio or hazard ratio with 95% confidence interval (CI); where time-to-event analysis was used, outcomes were expressed as odds ratio with 95% CI. Continuous data were expressed as difference in means (MD) with 95% CI, and standardized mean difference (SMD) was used when different outcome scales were pooled.
RESULTS:
Seven original studies, comprising a total of 732 adults, were included in this meta-analysis. Compared to SC alone, CHM plus SC had a superior effect on the change of symptom and sign score (-1.30 by SMD, 95% CI [-2.43, -0.16]; 3 studies; n = 261, P = 0.03), on inflammatory marker C-reactive protein (CRP, mg/L; -11.82 by MD, 95% CI [-17.95, -5.69]; 5 studies; n = 325, P = 0.0002), on number of patients with improved lung CT scans (1.34 by risk ratio, 95% CI [1.19, 1.51]; 4 studies; n = 489, P < 0.00001). No significant adverse events were recorded in the included RCTs.
CONCLUSION
Current evidence shows that CHM, as an adjunct treatment with standard care, helps to improve treatment outcomes in COVID-19 cases.
Betacoronavirus
;
drug effects
;
Coronavirus Infections
;
drug therapy
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
2.Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial.
Yuan-Yuan QIN ; Yi-Hong ZHOU ; Yan-Qiu LU ; Feng SUN ; Sen YANG ; Vijay HARYPURSAT ; Yao-Kai CHEN
Chinese Medical Journal 2020;133(9):1080-1086
BACKGROUND:
At the end of 2019, a novel coronavirus outbreak causative organism has been subsequently designated the 2019 novel coronavirus (2019-nCoV). The effectiveness of adjunctive glucocorticoid therapy in the management of 2019-nCoV-infected patients with severe lower respiratory tract infections is not clear, and warrants further investigation.
METHODS:
The present study will be conducted as an open-labeled, randomized, controlled trial. We will enrol 48 subjects from Chongqing Public Health Medical Center. Each eligible subject will be assigned to an intervention group (methylprednisolone via intravenous injection at a dose of 1-2 mg/kg/day for 3 days) or a control group (no glucocorticoid use) randomly, at a 1:1 ratio. Subjects in both groups will be invited for 28 days of follow-up which will be scheduled at four consecutive visit points. We will use the clinical improvement rate as our primary endpoint. Secondary endpoints include the timing of clinical improvement after intervention, duration of mechanical ventilation, duration of hospitalization, overall incidence of adverse events, as well as rate of adverse events at each visit, and mortality at 2 and 4 weeks.
DISCUSSION:
The present coronavirus outbreak is the third serious global coronavirus outbreak in the past two decades. Oral and parenteral glucocorticoids have been used in the management of severe respiratory symptoms in coronavirus-infected patients in the past. However, there remains no definitive evidence in the literature for or against the utilization of systemic glucocorticoids in seriously ill patients with coronavirus-related severe respiratory disease, or indeed in other types of severe respiratory disease. In this study, we hope to discover evidence either supporting or opposing the systemic therapeutic administration of glucocorticoids in patients with severe coronavirus disease 2019.
TRIAL REGISTRATION
ClinicalTrials.gov, ChiCTR2000029386, http://www.chictr.org.cn/showproj.aspx?proj=48777.
Betacoronavirus
;
drug effects
;
Coronavirus Infections
;
drug therapy
;
Glucocorticoids
;
adverse effects
;
therapeutic use
;
Humans
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
;
Randomized Controlled Trials as Topic
;
Severity of Illness Index
4.Chloroquine phosphate: therapeutic drug for COVID-19.
Journal of Southern Medical University 2020;40(4):586-594
Since the outbreak of coronavirus disease 2019 (COVID-19) in the late 2019, a variety of antiviral drugs have been used in the first-line clinical trial. The Diagnostic and Treatment Protocol for COVID-19 (Trial Version 6) in China recommends chloroquine phosphate for the first time as an anti-coronavirus trial drug. As a classic drug for treatment of malaria and rheumatism, chloroquine phosphate has been used clinically for more than 80 years, and has also shown good results in the treatment of various viral infections. As the plasma drug concentration varies greatly among different races and individuals and due to its narrow treatment window, chloroquine in likely to accumulate in the body to cause toxicity. Among the treatment regimens recommended for COVID-19, reports concerning the safety of a short-term high-dose chloroquine regimen remain scarce. In this review, the authors summarize the current research findings of chloroquine phosphate in the treatment of COVID-19, and examine the pharmacokinetic characteristics, antiviral therapy, the therapeutic mechanism and safety of chloroquine.
Antiviral Agents
;
Betacoronavirus
;
drug effects
;
China
;
Chloroquine
;
analogs & derivatives
;
therapeutic use
;
Coronavirus Infections
;
drug therapy
;
Humans
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
6.Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids.
Sheng ZHAGN ; Danping LI ; Huazhong CHEN ; Dan ZHENG ; Yiping ZHOU ; Baoguo CHEN ; Weiwu SHI ; Ronghai LIN
Journal of Zhejiang University. Medical sciences 2020;49(2):220-226
OBJECTIVE:
To investigate the effect of corticosteroids therapy on the inflammatory response in a critically ill coronavirus disease 2019 (COVID-19) patient.
METHODS:
A 55-year old female patient with critical ill COVID-19 was admitted in Taizhou Hospital on January 19, 2020. The patient was treated with methylprednisolone 80 mg on the 2nd day after admission. Thereafter, the dose was adjusted in a timely manner and the therapy lasted for 13 days. The peripheral lymphocyte subsets (CD3T, CD4 T, CD8 T, NK cells, B cells), as well as serum levels of lymphocyte factors (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ) were dynamically monitored.
RESULTS:
On D1 of admission, the numbers of peripheral blood CD3 T, CD4 T, CD8 T, and NK cells were significantly lower than the normal range. With the improvement of the disease, the numbers of CD3 T, CD8 T and CD4 T cells gradually recovered and showed a linear growth trend (linear fitting equation: =18.59+109.4, <0.05). On D2 of admission, the patient's IL-6 and IL-10 levels were significantly higher than normal values, IFN-γ was at a normal high value, and then rapidly decreased; IL-2, IL-4, and TNF-α were all in the normal range. On the D6 and D7, the IL-6 and IL-10 decreased to the normal range for the first time. On the D18, the sputum virus nucleic acid test was negative for the first time, and the fecal virus nucleic acid test was still positive; on the D20 the sputum and fecal virus nucleic acid test were both negative. On D34, the patient recovered and was discharged. At the discharge the muscle strength score of the patient was 44 and the daily life ability evaluation was 90.
CONCLUSIONS
In the absence of effective antiviral drugs, early use of appropriate doses of corticosteroids in critically ill patient with COVID-19 can quickly alleviate inflammatory response and improve clinical symptoms, however, it may reduce the number of T cells, and to adjust the dose in time is necessary.
Betacoronavirus
;
isolation & purification
;
Cell Count
;
Coronavirus Infections
;
diagnosis
;
drug therapy
;
immunology
;
physiopathology
;
Critical Illness
;
Cytokines
;
blood
;
Female
;
Humans
;
Methylprednisolone
;
administration & dosage
;
adverse effects
;
Middle Aged
;
Pandemics
;
Pneumonia, Viral
;
diagnosis
;
drug therapy
;
immunology
;
physiopathology
;
T-Lymphocyte Subsets
;
drug effects
;
Treatment Outcome
7.Pharmaceutical care for severe and critically ill patients with COVID-19.
Saiping JIANG ; Lu LI ; Renping RU ; Chunhong ZHANG ; Yuefeng RAO ; Bin LIN ; Rongrong WANG ; Na CHEN ; Xiaojuan WANG ; Hongliu CAI ; Jifang SHENG ; Jianying ZHOU ; Xiaoyang LU ; Yunqing QIU
Journal of Zhejiang University. Medical sciences 2020;49(2):158-169
Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on ( 6), and -19: , we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.
Adrenal Cortex Hormones
;
adverse effects
;
therapeutic use
;
Anti-Bacterial Agents
;
therapeutic use
;
Antiviral Agents
;
adverse effects
;
therapeutic use
;
Betacoronavirus
;
isolation & purification
;
Coronavirus Infections
;
drug therapy
;
Critical Illness
;
Drug Therapy
;
Humans
;
Nutritional Support
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
;
Probiotics
;
administration & dosage
8.Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model.
Hua-Hao FAN ; Li-Qin WANG ; Wen-Li LIU ; Xiao-Ping AN ; Zhen-Dong LIU ; Xiao-Qi HE ; Li-Hua SONG ; Yi-Gang TONG
Chinese Medical Journal 2020;133(9):1051-1056
BACKGROUND:
Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those institutions without such facilities or 2019-nCoV. This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV-related coronavirus model.
METHODS:
A 2019-nCoV-related pangolin coronavirus GX_P2V/pangolin/2017/Guangxi was described. Whether GX_P2V uses angiotensin-converting enzyme 2 (ACE2) as the cell receptor was investigated by using small interfering RNA (siRNA)-mediated silencing of ACE2. The pangolin coronavirus model was used to identify drug candidates for treating 2019-nCoV infection. Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic effects on Vero E6 cells by GX_P2V infection. The anti-viral activities and anti-viral mechanisms of potential drugs were further investigated. Viral yields of RNAs and infectious particles were quantified by quantitative real-time polymerase chain reaction (qRT-PCR) and plaque assay, respectively.
RESULTS:
The spike protein of coronavirus GX_P2V shares 92.2% amino acid identity with that of 2019-nCoV isolate Wuhan-hu-1, and uses ACE2 as the receptor for infection just like 2019-nCoV. Three drugs, including cepharanthine (CEP), selamectin, and mefloquine hydrochloride, exhibited complete inhibition of cytopathic effects in cell culture at 10 μmol/L. CEP demonstrated the most potent inhibition of GX_P2V infection, with a concentration for 50% of maximal effect [EC50] of 0.98 μmol/L. The viral RNA yield in cells treated with 10 μmol/L CEP was 15,393-fold lower than in cells without CEP treatment ([6.48 ± 0.02] × 10vs. 1.00 ± 0.12, t = 150.38, P < 0.001) at 72 h post-infection (p.i.). Plaque assays found no production of live viruses in media containing 10 μmol/L CEP at 48 h p.i. Furthermore, we found CEP had potent anti-viral activities against both viral entry (0.46 ± 0.12, vs.1.00 ± 0.37, t = 2.42, P < 0.05) and viral replication ([6.18 ± 0.95] × 10vs. 1.00 ± 0.43, t = 3.98, P < 0.05).
CONCLUSIONS
Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research. CEP, selamectin, and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection. Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and further study of CEP for treatment of 2019-nCoV infection is warranted.
Betacoronavirus
;
drug effects
;
genetics
;
Cell Line
;
Clinical Laboratory Techniques
;
Coronavirus Infections
;
diagnosis
;
drug therapy
;
Drug Approval
;
Humans
;
Pandemics
;
Pneumonia, Viral
;
diagnosis
;
drug therapy
;
RNA, Small Interfering
;
genetics
;
Real-Time Polymerase Chain Reaction
;
Viral Load
9.Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors.
Lu TIAN ; Wenjun LIU ; Lei SUN
Chinese Journal of Biotechnology 2020;36(4):605-611
Cyclophilin A (CypA) is a widely distributed and highly conserved protein in organisms. It has peptidyl-prolyl cis/trans isomerase activity and is a receptor for cyclosporin A (CsA). Coronaviruses are enveloped, single-stranded, positive-sense RNA viruses. Seven types of coronaviruses are currently known to infect humans, among which SARS-CoV, MERS-CoV, and SARS-CoV-2 are fatal for humans. It is well established that CypA is essential for the replication of various coronaviruses such as SARS-CoV, CoV-229E, CoV-NL63, and FCoV. Additionally, CsA and its derivatives (ALV, NIM811, etc.) have obvious inhibitory effects on a variety of coronaviruses. These results suggest that CypA is a potential antiviral target and the existing drug CsA might be used as an anti-coronavirus drug. At the end of 2019, SARS-CoV-2 raged in China, which seriously theatern human health and causes huge economic lases. In view of this, we describe the effects of CypA on the replication of coronaviruses and the antiviral activities of its inhibitors, which will provide the scientific basis and ideas for the development of antiviral drugs for SARS-CoV-2.
Antiviral Agents
;
pharmacology
;
therapeutic use
;
Betacoronavirus
;
drug effects
;
growth & development
;
Coronavirus
;
drug effects
;
growth & development
;
Coronavirus Infections
;
drug therapy
;
epidemiology
;
virology
;
Cyclophilin A
;
antagonists & inhibitors
;
Cyclosporine
;
chemistry
;
pharmacology
;
therapeutic use
;
Humans
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
;
epidemiology
;
virology
;
SARS Virus
;
drug effects
;
growth & development
;
Virus Replication
;
drug effects
10.Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future.
Chinese Journal of Biotechnology 2020;36(4):571-592
The ongoing outbreak of the coronavirus disease 2019 (COVID-19) as named by the World Health Organization has millions of confirmed cases around the world and has claimed hundreds of thousands of lives. The virus was named SARS-CoV-2 in February by International Committee on Taxonomy of Viruses. COVID-19 presents as fever, dry cough, dyspnea, headache and pneumonia. In a small subset of severe cases, the disease quickly progresses to respiratory failure and even death. Since the 21st century, there have been three major outbreaks caused by human coronaviruses, including the severe acute respiratory syndrome (SARS) that broke out in 2003, the Middle East respiratory syndrome (MERS) in 2012, and the recent pandemic of COVID-19. Since 2003, significant progress has been made in the study of SARS-CoV and MERS-CoV concerning their natural origins, pathogenesis, antiviral development and vaccine design. Since SARS-CoV-2 and SARS-CoV are closely related, previous findings on SARS-CoV are highly relevant to a better understanding as well as diagnosis, treatment, prevention and control of SARS-CoV-2. In this review, we highlight recent progresses in the field; compare the biological characteristics of SARS-CoV and SARS-CoV-2; summarize the urgently-needed diagnostic, treatment, prevention and control options; and provide future perspectives for the outcome of the outbreak and research questions to be answered, including some of the difficulties in vaccine development. Hopefully, our comments and suggestions would prove useful for the control of the SARS-CoV-2 epidemic in China and the world.
Antiviral Agents
;
pharmacology
;
therapeutic use
;
Betacoronavirus
;
drug effects
;
immunology
;
pathogenicity
;
Coronavirus Infections
;
diagnosis
;
prevention & control
;
therapy
;
virology
;
Humans
;
Middle East Respiratory Syndrome Coronavirus
;
drug effects
;
immunology
;
pathogenicity
;
Pandemics
;
prevention & control
;
Pneumonia, Viral
;
diagnosis
;
prevention & control
;
therapy
;
virology
;
SARS Virus
;
drug effects
;
immunology
;
pathogenicity
;
Severe Acute Respiratory Syndrome
;
diagnosis
;
prevention & control
;
therapy
;
virology
;
Viral Vaccines